Unibest
← Back to patent-cliff list

Deuterated ruxolitinib

Tier C — Watch / trade

Deuterated ruxolitinib

Concert Pharmaceuticals Inc
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:JAK2, JAK1

Brand:LEQSELVI

Indications (approved):Alopecia areata

Regional status

US
Approved
2024-07-25
EU
Phase III
2020-11-23
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 8 · Total yield 19 mg (Deuterated Ruxolitinib)
D-RUXO-00168375-92-8D-RUXO-002105-53-3D-RUXO-0031254047-32-9D-RUXO-0041513884-11-1D-RUXO-0051801457-17-9D-RUXO-006—D-RUXO-007—D-RUXO-0081146629-77-7D-RUXO-009—D-RUXO-010—Deuterated Ruxolitinib1513883-39-0API · Deuterated ruxolitinib
CodeCAS No.Intermediate
D-RUXO-00168375-92-81,4-dibromobutane-1,1,2,2,3,3,4,4-d8
D-RUXO-002105-53-3Availablediethyl malonate
D-RUXO-0031254047-32-9diethyl cyclopentane-1,1-dicarboxylate-d8
D-RUXO-0041513884-11-1cyclopentane-1-carboxylic-2,2,3,3,4,4,5,5-d8 acid
D-RUXO-0051801457-17-9N-methoxy-N-methylcyclopentane-1-carboxamide-2,2,3,3,4,4,5,5-d8
D-RUXO-006-cyclopentane-2,2,3,3,4,4,5,5-d8-1-carbaldehyde
D-RUXO-007-(E)-3-(cyclopentyl-2,2,3,3,4,4,5,5-d8)acrylonitrile
D-RUXO-0081146629-77-7Available(4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
D-RUXO-009-(4-(1-(2-cyano-1-(cyclopentyl-2,2,3,3,4,4,5,5-d8)ethyl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
D-RUXO-010-(R)-(4-(1-(2-cyano-1-(cyclopentyl-2,2,3,3,4,4,5,5-d8)ethyl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
Deuterated Ruxolitinib1513883-39-0(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(cyclopentyl-2,2,3,3,4,4,5,5-d8)propanenitrile

Frequently asked questions

What are the approved indications of Deuterated ruxolitinib?

Approved indications include: Alopecia areata.

When does the Deuterated ruxolitinib patent expire?

No public expiry year is available for Deuterated ruxolitinib yet; this page updates once verified.

How many synthesis routes are recorded for Deuterated ruxolitinib?

1 synthesis routes are recorded; the shortest is 8 steps with 19 mg (Deuterated Ruxolitinib) total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Deuterated ruxolitinib intermediates?

2 intermediate CAS of Deuterated ruxolitinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Deuterated ruxolitinib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27